Cholinesterase inhibitors in vascular cognitive impairment.
نویسنده
چکیده
Vascular Cognitive Impairment (VCI) includes vascular dementia, mixed dementia (Alzheimer’s disease [AD] with cerebrovascular disease), and vascular mild cognitive impairment, and it is a common cause of cognitive dysfunction1. Some may even contend that it is the most common cause of cognitive impairment. This is based principally on clinicopathological data showing that most aged individuals with significant cognitive impairment have mixed vascular and neurodegenerative neuropathology2. Vascular risk factor prevention and treatment are a mainstay of VCI management. Based on data showing disruption of cholinergic pathways in vascular dementia, cholinesterase inhibitors (ChEI) have also been widely used for symptomatic treatment3. Following a comprehensive review and analysis of the literature, the third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD) published in 2007 concluded that there was fair evidence for a modest benefit of donepezil on clinical outcomes in vascular dementia4. The third CCCDTD also concluded that there was fair evidence of modest benefit of galantamine in mixed AD with cerebrovascular disease. Similarly, the American Stroke Association and American Heart Association in their statement on Vascular Contribution to Cognitive Impairment and Dementia recommended donepezil for “cognitive enhancement” in patients with vascular dementia, and galantamine for patients with mixed AD with vascular dementia1. Clinical trials in VCI published since then have shown positive results for other cholinesterase inhibitors in mixed dementia, but inconsistent results in vascular dementia. This led the fourth and most recent CCCDTD, published in 2012, to recommend all ChEIs as symptomatic treatment options in mixed dementia5. However, it concluded that there was insufficient evidence to recommend for or against symptomatic treatment with ChEIs in vascular dementia. Vascular Cognitive Impairment, particularly vascular dementia, usually presents with a fronto-sub-cortical pattern of impairment with prominent executive dysfunction and relative sparing of memory, which is distinct from the typical clinical picture seen in cortical dementias such as AD. This poses a diagnostic challenge in clinical practice as commonly used cognitive screening tools such as Folstein’s Mini-Mental Status Examination (MMSE) are limited by their capacity to capture executive dysfunction. More recently developed screening tests, the Montreal Cognitive Assessment (MOCA) being a salient example6, have refined executive function evaluation and are better suited for screening of VCI7. The clinical pattern of VCI also constitutes a challenge in the selection of appropriate and responsive outcome measures in clinical trials of pharmacological interventions. The study published by Rockwood et al, in this issue of the Canadian Journal of Neurological Sciences deals specifically with this topic of using appropriate outcome measures in clinical trials of VCI and translating the results of Cholinesterase Inhibitors in Vascular Cognitive Impairment
منابع مشابه
Effect of Donepezil on Cognitive Disorders Due to the Selective Serotonin Reuptake Inhibitors in the Patients with Major Depressive Disorder
Introduction: Many factors cause cognitive impairment, including medication, such as selective serotonine reuptake inhibitor drugs use. On the other hand, many drugs are used in cognitive impairment therapy, including donepezil, which act by inhibiting the cholinesterase enzyme and increase brain acetylcholine. Methods: This study was a double-blind controlled randomized controlled clinical tr...
متن کاملEmerging therapies for vascular dementia and vascular cognitive impairment.
BACKGROUND Cerebrovascular disease (CVD) and ischemic brain injury secondary to cardiovascular disease are common causes of dementia and cognitive decline in the elderly. CVD also contributes to cognitive loss in Alzheimer disease (AD). SUMMARY Progress in understanding vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in promising symptomatic and preventive treatme...
متن کاملHave last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review
BACKGROUND Intention-to-treat analysis is used in the analysis of randomized controlled trials to preserve trial power in the presence of missing subject data as well as to control for both known and unknown confounding factors. One form of intention-to-treat analysis is last-observation-carried-forward (LOCF). Concerns exist regarding whether it is appropriate to use LOCF in analyses involving...
متن کاملTreatment for mild cognitive impairment: a systematic review and meta-analysis.
BACKGROUND The effectiveness of treatments for mild cognitive impairment is uncertain. The aim of this review was to evaluate the effectiveness and harms of treatment for mild cognitive impairment in adults 65 years of age and older. METHODS We searched MEDLINE, Embase and Cochrane Central (December 2012-December 2014); citations from 2 systematic reviews were considered for inclusion. We inc...
متن کاملCognitive pharmacotherapy of Alzheimer's disease and other dementias.
OBJECTIVE The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders. METHOD A Medline search was conducted for RCTs, using the following key words: Alzheimer's disease, dementia, therapy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
دوره 40 4 شماره
صفحات -
تاریخ انتشار 2013